NASDAQ: SLXN
Silexion Therapeutics Corp Stock

$1.27-0.08 (-5.93%)
Updated Feb 13, 2025
SLXN Price
$1.27
Fair Value Price
$0.54
Market Cap
$2.04M
52 Week Low
$0.58
52 Week High
$122.02
P/E
-0.01x
P/B
-0.44x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$7.46M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.67
Operating Cash Flow
-$9M
Beta
0.19
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

SLXN Overview

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine SLXN's potential to beat the market

FStrong Sell
  • Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More

Zen Rating Component Grades

F
Value
D
Growth
F
Momentum
C
Sentiment
C
Safety
F
Financials
F
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
SLXN
Ranked
#559 of 560

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important SLXN news, forecast changes, insider trades & much more!

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SLXN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SLXN ($1.27) is overvalued by 134.01% relative to our estimate of its Fair Value price of $0.54 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SLXN ($1.27) is not significantly undervalued (134.01%) relative to our estimate of its Fair Value price of $0.54 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SLXN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SLXN due diligence checks available for Premium users.

Valuation

SLXN fair value

Fair Value of SLXN stock based on Discounted Cash Flow (DCF)

Price
$1.27
Fair Value
$0.54
Overvalued by
134.01%
SLXN ($1.27) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SLXN ($1.27) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SLXN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SLXN price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.01x
Industry
-174.82x
Market
38.39x

SLXN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-0.44x
Industry
4.78x

SLXN's financial health

Profit margin

Revenue
$0.0
Net Income
$11.9M
Profit Margin
0%
SLXN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$3.1M
Liabilities
$7.7M
Debt to equity
-1.67
SLXN's short-term liabilities ($3.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SLXN's long-term liabilities ($4.08M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SLXN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SLXN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.7M
Investing
-$16.0k
Financing
$2.9M
SLXN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SLXN vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
SLXNF$2.04M-5.93%-0.01x-0.44x
CYCC$2.06M+6.84%-0.04x-2.13x
EYEND$2.06M+3.24%-0.03x0.55x
PCSAD$2.00M+0.16%-0.13x0.54x
VINCD$2.15M+2.40%-0.06x0.24x

Silexion Therapeutics Stock FAQ

What is Silexion Therapeutics's quote symbol?

(NASDAQ: SLXN) Silexion Therapeutics trades on the NASDAQ under the ticker symbol SLXN. Silexion Therapeutics stock quotes can also be displayed as NASDAQ: SLXN.

If you're new to stock investing, here's how to buy Silexion Therapeutics stock.

What is the 52 week high and low for Silexion Therapeutics (NASDAQ: SLXN)?

(NASDAQ: SLXN) Silexion Therapeutics's 52-week high was $122.02, and its 52-week low was $0.58. It is currently -98.96% from its 52-week high and 120.87% from its 52-week low.

How much is Silexion Therapeutics stock worth today?

(NASDAQ: SLXN) Silexion Therapeutics currently has 1,603,090 outstanding shares. With Silexion Therapeutics stock trading at $1.27 per share, the total value of Silexion Therapeutics stock (market capitalization) is $2.04M.

Silexion Therapeutics stock was originally listed at a price of $95.94 in Feb 17, 2021. If you had invested in Silexion Therapeutics stock at $95.94, your return over the last 3 years would have been -98.68%, for an annualized return of -76.34% (not including any dividends or dividend reinvestments).

How much is Silexion Therapeutics's stock price per share?

(NASDAQ: SLXN) Silexion Therapeutics stock price per share is $1.27 today (as of Feb 13, 2025).

What is Silexion Therapeutics's Market Cap?

(NASDAQ: SLXN) Silexion Therapeutics's market cap is $2.04M, as of Feb 14, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Silexion Therapeutics's market cap is calculated by multiplying SLXN's current stock price of $1.27 by SLXN's total outstanding shares of 1,603,090.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.